Obiettivo Many efficient drugs have been designed to treat neurological disorders, but have failed in the clinic because they were toxic, could not cross the blood-brain barrier, and/or had deleterious side effects in healthy regions. I propose a conceptual breakthrough to solve these three issues, with minimally-invasive organic electronic ion pumps (OEIPs) to provide targeted treatment where and when it is needed. I will use epilepsy as the disease model because of its high rate of drug-resistance (30%) and will offer concrete opportunities for clinical transfer of such state-of-the-art technology.The clinical problem: Resective surgery is frequently the last option available to a patient with drug-resistant epilepsy (> 1 million persons in the EU). However, surgery fails in 30% of the cases and can have deleterious consequences with severe postoperative neurological deficits (impaired motor function, speech and memory). Furthermore, some cases of epilepsy are simply untreatable surgically because resective surgery would leave unacceptable damage to core functions. Clearly, a new therapeutic approach is needed when neurosurgery is not possible or deemed too risky.The OEIP solution: As I have demonstrated, OEIPs combine state-of-the-art organic electronics and pharmacology to control epileptiform activity in vitro by directly delivering inhibitory neurotransmitters on-demand. I additionally demonstrated that thin-film flexible organic electronics can be used to create minimally-invasive depth probes for implantation which significantly reduced tissue damage compared to standard rigid implants in vivo. I will integrate OEIPs on such probes creating devices which will have both the high-quality recordings provided by the organic electrodes for electrophysiological seizure detection and the molecular delivery capability of the OEIP for seizure intervention. The devices will be a closed-loop system to detect seizure onset and intervene in the affected brain region. Campo scientifico medical and health sciencesbasic medicineneurologyepilepsymedical and health sciencesclinical medicinesurgerymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemedical and health sciencesmedical biotechnologytissue engineeringartificial pancreascontinuous glucose monitorsmedical and health sciencesbasic medicineneurologyparkinson Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-2016-STG - ERC Starting Grant Invito a presentare proposte ERC-2016-STG Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-STG - Starting Grant Istituzione ospitante UNIVERSITE D'AIX MARSEILLE Contribution nette de l'UE € 1 261 250,00 Indirizzo BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille Francia Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 636 250,00 Beneficiari (2) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto UNIVERSITE D'AIX MARSEILLE Francia Contribution nette de l'UE € 1 261 250,00 Indirizzo BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille Mostra sulla mappa Regione Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 636 250,00 Terza parte Soggetto giuridico diverso da un subappaltatore che è affiliato o legalmente collegato a un partecipante. Il soggetto svolge le attività secondo le condizioni stabilite nell’accordo di sovvenzione, fornisce beni o servizi per l’azione, ma non ha sottoscritto l’accordo di sovvenzione. Una terza parte rispetta le regole applicabili al suo partecipante correlato ai sensi dell’accordo di sovvenzione per quanto riguarda l’ammissibilità dei costi e il controllo delle spese. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Francia Contribution nette de l'UE € 375 000,00 Indirizzo RUE DE TOLBIAC 101 75654 Paris Mostra sulla mappa Regione Ile-de-France Ile-de-France Paris Tipo di attività Research Organisations Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 375 000,00
